TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04562584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyHomeDoc
Description: MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
Study: NCT00845026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: 10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
Study: NCT04692220

Intervention type: OTHER
Intervention: Detection of Adverse Drug Events or Drug-Related Problems
Description: Detection of Adverse Drug Events or Drug-Related Problems

Intervention type: OTHER
Intervention: Detection of Adverse Drug Events or Drug-Related Problems
Description: Detection of Adverse Drug Events or Drug-Related Problems
Study: NCT00323674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polysoft Mesh
Description: Polysoft Mesh is used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Weight Mesh
Description: Light Weight Mesh is used.
Study: NCT00971204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioFocus HeartLight Endoscopic Ablation System
Description: PVI ablation
Study: NCT03844568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nocturnal nasal continuous positive airway pressure
Description: applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
Study: NCT01190306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The VEGA UV-A Illumination System
Description: This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin is a solution that will be delivered to the treatment area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin is a solution that will be delivered to the treatment area
Study: NCT03817632

Intervention type: DEVICE
Intervention: Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1
Description: Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1

Intervention type: DEVICE
Intervention: Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
Description: Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
Study: NCT02784860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
Study: NCT02174900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL) combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
Study: NCT03337737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extreme Endurance
Description: Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03598452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
Study: NCT02542150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetate
Description: acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcohol
Description: a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan.
Study: NCT00652379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Pegvisomant s.c 15-30 mg 2 times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin analog (lanreotide or octreotide)
Description: Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin analog (lanreotide or octreotide)
Description: Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
Study: NCT06191510

Intervention type: PROCEDURE
Intervention: Bio-Oss Exposed
Description: Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.

Intervention type: PROCEDURE
Intervention: Mucograft Exposed
Description: Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
Study: NCT04839237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide;metformin
Description: The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
Study: NCT03493854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
Study: NCT03005379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Therapy (FMT)
Description: Oral capsule-delivered FMT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule-delivered placebo
Study: NCT01968681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alexandrite laser
Description: 3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
Study: NCT01052805

Intervention type: PROCEDURE
Intervention: harvest nerve
Description: harvest nerve from cadaveric donor and patients receiving nerve graft operation
Study: NCT01222871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone soaked nasopore dressing
Study: NCT03493854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
Study: NCT01222871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline soaked sponge
Description: saline soaked sponge
Study: NCT03530033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Local injection of lidocaine reduces muscle tremor
Study: NCT04606212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study: NCT03555890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine IRT 5 mg
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine IRT 5 mg
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
Study: NCT00396656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: 100 mg tablets orally once a day (od) in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: 100 mg tablets orally once a day (od) in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ))
Description: 12.5 or 25 mg tablets orally once a day (od) in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ))
Description: 12.5 or 25 mg tablets orally once a day (od) in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg, 160 mg, or 320 mg tablets orally once a day in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
Study: NCT04122417

Intervention type: OTHER
Intervention: The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby
Description: The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
Study: NCT03555890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine IRT 5 mg
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
Study: NCT02821026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omental Islet transplant
Description: The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
Study: NCT01836731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic Intervention
Description: The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimum Intervention
Description: The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers.
Study: NCT02095548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690, 0.03mg/2mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690, 0.07mg/2mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690, 0.23mg/2mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02547220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cinryze®
Description: Participants will receive 5000 Units of CINRYZE (50 millilitre \[mL\] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 7 doses of matched placebo over 13 days of treatment.
Study: NCT02551562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NuDerm® System
Description: The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Basic skin care regimen
Study: NCT00869622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35 mgs/week + calcium and vit d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Calcium and Vitamin D
Description: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
Study: NCT03721796

Intervention type: OTHER
Intervention: Audio recording of initial consultation and debriefing interviews.
Description: Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.

Intervention type: OTHER
Intervention: Audio recording of initial consultation and debriefing interviews.
Description: Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.
Study: NCT00552643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspension of polystyrene beads (POLYHEAL 1)
Description: Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
Study: NCT02455206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseling
Description: 5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT00937365

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroemotional Technique (NET)
Description: Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
Study: NCT02528877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoeitic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo hematopoietic stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT01788826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh
Description: Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No prophylactic mesh closure
Description: Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
Study: NCT03850483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle topical cream
Study: NCT00581672

Intervention type: BEHAVIORAL
Intervention: questionnaires of quality of life
Description: Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
Study: NCT01080482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 5 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 5 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule